BPC-157 10mg

BPC-157 10mg

Gastric Pentadecapeptide · Angiogenesis · Tendon and Ligament · Research Only

What is it and how does it work?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective sequence of human gastric juice. Preclinical literature describes multiple documented pathways of action in animal models: upregulation of VEGFR2 with an angiogenic effect, activation of the Akt-eNOS and Src-Caveolin-1-eNOS cascades on vasomotor tone, and an increase in growth hormone receptor in tendon fibroblasts with in vitro tenocyte proliferation (Hsieh et al., Sci Rep 2020 PMC7555539; Chang et al., J Appl Physiol 2011).

Extensive preclinical evidence (Sikiric et al., University of Zagreb, since the 90s) in mouse and rat models: Achilles tendon healing, collateral ligament, gastric mucosa, intestinal anastomosis, and ulcerative colitis (PL-14736, Pliva Phase II trials). A systematic review from 2025 (Vasireddi et al., Am J Sports Med 2025 PMID 40756949) of 36 studies documents reduction in pro-inflammatory cytokines and modulation of tissue repair pathways in experimental models. No human use approved by FDA — research material only.

Reconstitution and dosage

• Vial 10 mg lyophilized
• Bacteriostatic water: 2 ml (standard rule: 1ml per 5mg)
• Resulting concentration: 5,000 mcg/mL
• Per unit U-100: 50 mcg · verification: 5,000 ÷ 100 = 50 mcg/u ✓
• Conservation Refrigerate at 2–8°C · Use within 28–30 days
• Performance Equivalent volume: 200 U-100 units per reconstituted vial

Volume Conversion Chart (U-100 syringe)

Documented evidence in research literature

Combinations reported in literature

• BPC-157 + TB-500 (preclinical literature ‘Wolverine’ stack): independent pathways — BPC-157 via VEGFR2/eNOS contributes to angiogenesis; TB-500 (Ac-SDKP sequence) contributes to cell migration. No reported mechanistic redundancy.
• BPC-157 + Tesamorelin/CJC-Ipa in regeneration studies: endogenous GH amplifies GH receptor upregulation that BPC-157 produces in tendon fibroblasts in experimental models.
• BPC-157 + GHK-Cu: act on different compartments according to the literature—BPC-157 in deep tissue (tendons, ligaments, mucosa); GHK-Cu in skin, fascia, and the extracellular matrix.
• BPC-157 + KPV: Both modulate anti-inflammatory pathways via distinct mechanisms in preclinical models—KPV via melanocortin MC1R; BPC-157 via NO/cytokines.

Practical notes

• Presentation 10mg allows for extended research without frequent vial replacement. Vial yield: 200 units total U-100.
• Documented via primary preclinical literature: SC and IP in rodents. Reported gastric stability also allows for oral exploration in preclinical studies.

Contraindications and precautions

• Research material only. Not FDA-approved for human use. No established human safety data. Preclinical literature reports theoretical caution in models with active cancer due to VEGF upregulation. Do not use in humans.

Research material only. Not approved for human use by the FDA. This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.

Research material only. It is not a medication. Not for human or animal use, not for diagnostic or therapeutic use.